Document Detail

Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction.
MedLine Citation:
PMID:  15966919     Owner:  NLM     Status:  MEDLINE    
The safety and efficacy of treating recently stented patients on combination antiplatelet therapy with warfarin for clinical indications in unknown. Therefore, we examined the use of warfarin in a population of patients with myocardial infarction (MI) treated with coronary stenting. We performed a retrospective analysis comparing patients who underwent successful coronary stenting for acute MI and were discharged on either warfarin and combination platelet therapy for clinical indications or combination antiplatelet therapy alone. There was a nonsignificant trend toward reinfarction at 6 and 12 months in warfarin-treated patients. Warfarin-treated patients had significantly higher rates of transfusion compared to nonwarfarin-treated patients at 12 months (21% vs 0%, P=0.028). There were no significant predictors of reinfarction in 6 and 12 months in multivariate analysis. These data demonstrate that warfarin anticoagulation, in combination with successful coronary stenting for acute MI and antiplatelet therapy, does not reduce risk of reinfarction but is associated with increased rates of transfusion.
Stephen J Mattichak; Pamela S Reed; Michael J Gallagher; Judith A Boura; William W O'Neill; Joel K Kahn
Related Documents :
15065149 - Late coronary stent thrombosis associated with exercise testing.
9786399 - Hemodynamic rounds series ii: coronary hemodynamics for angioplasty and stenting after ...
16721209 - Very late thrombosis after sirolimus-eluting stent implantation.
19050419 - Paclitaxel-eluting versus bare-metal stents in acute st elevation myocardial infarction...
15940439 - Incications and complications of invasive diagnostic procedures and percutaneous corona...
14517939 - Bare delivery of medium and large stents in patients with congenital heart disease.
17371199 - Vernakalant (rsd1235): a novel, atrial-selective antifibrillatory agent.
687479 - Re-entry via mahaim fibres as a possible basis for tachycardia.
11951789 - Ace inhibitors in cardiovascular diseases.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of interventional cardiology     Volume:  18     ISSN:  0896-4327     ISO Abbreviation:  J Interv Cardiol     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-21     Completed Date:  2005-09-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8907826     Medline TA:  J Interv Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  163-6     Citation Subset:  IM    
Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use*
Blood Vessel Prosthesis Implantation / instrumentation*
Coronary Angiography
Drug Therapy, Combination
Follow-Up Studies
Middle Aged
Myocardial Infarction / drug therapy*,  radiography,  surgery
Platelet Aggregation Inhibitors / therapeutic use*
Postoperative Period
Recurrence / prevention & control
Retrospective Studies
Risk Factors
Treatment Outcome
Warfarin / therapeutic use*
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
Next Document:  Thrombolysis increases the risk of free wall rupture in patients with acute myocardial infarction un...